Belite Bio (NASDAQ: BLTE) CSO sells 1,000 ADS under 10b5-1 plan

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Belite Bio Chief Scientific Officer Nathan L. Mata sold a total of 1,000 American depositary shares in open-market transactions on April 29, 2026. The sales occurred at weighted average prices ranging from about $154.22 to $158.21, according to the filing footnotes.

The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. After these sales, Mata directly holds 5,666 ADS of Belite Bio.

Insider Trade Summary 10b5-1

Net Seller: 1,000 shares ($155,817)

Net Sell 5 txns

Insider MATA NATHAN L.

Role Chief Scientific Officer

Sold 1,000 shs ($156K)

Type	Security	Shares	Price	Value
Sale	American depositary share	278	$154.578	$43K
Sale	American depositary share	259	$155.5228	$40K
Sale	American depositary share	339	$156.4304	$53K
Sale	American depositary share	102	$157.3859	$16K
Sale	American depositary share	22	$158.1941	$3K

Holdings After Transaction: American depositary share — 6,388 shares (Direct, null)

Footnotes (1)

Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025. Represents the weighted average price of shares sold at prices that ranged from $154.22 to $154.96. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $155.02 to $155.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $156 to $156.96. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $157 to $157.9. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $158.03 to $158.21. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 1,000 ADS Post-transaction holdings: 5,666 ADS Lowest weighted average sale price range: $154.22–$154.96 +3 more

6 metrics

Shares sold 1,000 ADS Open-market sales on April 29, 2026 by CSO Nathan L. Mata

Post-transaction holdings 5,666 ADS Direct ownership after the reported sales

Lowest weighted average sale price range $154.22–$154.96 Price range referenced in a Form 4 footnote

Highest weighted average sale price range $158.03–$158.21 Price range referenced in a Form 4 footnote

Number of sale transactions 5 sales Non-derivative open-market sales of ADS

Trading plan adoption date December 10, 2025 Date CSO adopted Rule 10b5-1 trading plan

Key Terms

American depositary share, Rule 10b5-1 trading plan, weighted average price

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"Represents the weighted average price of shares sold at prices that ranged from $154.22 to $154.96."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 Insider Transactions: What Each Field Means →

04/30/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MATA NATHAN L.

(Last)

(First)

(Middle)

7708 MARKER ROAD

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
American depositary share⁽¹⁾	04/29/2026		S⁽²⁾		278	D	$154.578⁽³⁾	6,388	D
American depositary share⁽¹⁾	04/29/2026		S⁽²⁾		259	D	$155.5228⁽⁴⁾	6,129	D
American depositary share⁽¹⁾	04/29/2026		S⁽²⁾		339	D	$156.4304⁽⁵⁾	5,790	D
American depositary share⁽¹⁾	04/29/2026		S⁽²⁾		102	D	$157.3859⁽⁶⁾	5,688	D
American depositary share⁽¹⁾	04/29/2026		S⁽²⁾		22	D	$158.1941⁽⁷⁾	5,666	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.

3. Represents the weighted average price of shares sold at prices that ranged from $154.22 to $154.96. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

4. Represents the weighted average price of shares sold at prices that ranged from $155.02 to $155.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

5. Represents the weighted average price of shares sold at prices that ranged from $156 to $156.96. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

6. Represents the weighted average price of shares sold at prices that ranged from $157 to $157.9. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

7. Represents the weighted average price of shares sold at prices that ranged from $158.03 to $158.21. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

	/s/ Nathan L. Mata	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Belite Bio (BLTE) report for Nathan L. Mata?

Belite Bio reported that Chief Scientific Officer Nathan L. Mata sold 1,000 ADS. The Form 4 shows open-market sales of American depositary shares totaling 1,000 on April 29, 2026, executed in several trades at different prices.

At what prices did the Belite Bio (BLTE) CSO sell shares in this Form 4?

The sales occurred at weighted average prices between about $154.22 and $158.21 per ADS. Footnotes state that each reported price is a weighted average of multiple trades within narrower price ranges on April 29, 2026.

How many Belite Bio (BLTE) shares does Nathan L. Mata hold after these sales?

After the reported sales, Nathan L. Mata holds 5,666 ADS directly. The Form 4 indicates this post-transaction balance of American depositary shares, reflecting his remaining direct ownership in Belite Bio following the 1,000-share disposition.

Were the Belite Bio (BLTE) insider sales under a Rule 10b5-1 trading plan?

Yes. The filing states the sales were made under a Rule 10b5-1 trading plan. A footnote explains the plan was adopted by Nathan L. Mata on December 10, 2025, indicating the transactions were pre-arranged rather than opportunistic.

What type of security did the Belite Bio (BLTE) CSO sell in this Form 4?

The transactions involved American depositary shares (ADS) of Belite Bio. Each ADS represents one ordinary share with a par value of US$0.0001 per share, according to the filing’s footnote describing the structure of the securities.

How many separate sale transactions did the Belite Bio (BLTE) Form 4 report?

The Form 4 reports five separate open-market sale transactions. The transaction summary shows five sales totaling 1,000 ADS, each at slightly different weighted average prices within specified trading ranges on April 29, 2026.